Population modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬
@imtadvances.bsky.social
@imtadvances.bsky.socialPopulation modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬
@jdevos.bsky.socialChina tests CAR-T therapies faster than the rest of the world but regulatory changes could slow them down.
#CARTCells
@imtadvances.bsky.socialThis review explores the bottom-up development of LGR5-targeting immunotherapeutics, showing how a highly specific α‑LGR5 antibody can be adapted into multiple modalities
📖 Read more: vist.ly/5ihju
#Immunotherapy #CancerResearch #CARTcells #PrecisionMedicine #OpenAccess
@jdevos.bsky.socialEarly but promising results with armored #CARTcells targeting glypican-3 and co-expressing IL-15 and IL-21 in pediatric hepatoblastoma. Step by step, CAR-T cells are beginning to make solid tumors addressable.
@currentmedscience.bsky.socialWhy is #CD44v6 exciting in AML?
#Decitabine treatment increases CD44v6 expression on DNMT3A-mutant AML cells, improving recognition & targeting by #CARTcells. A promising step toward precision #Immunotherapy. #medsky
Read: doi.org/10.1007/s115...
#currentmedicalscience #Oncology
@jem.orgIntravesical mesothelin-based #CARTcells targeting MUC16 effectively control #BladderCancer in preclinical models. From Parwiz Abrahimi, Renier Brentjens, Jedd Wolchok, Taha Merghoub et al.: rupress.org/jem/article/...
Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia
